Similar articles for PMID: 30711996

Year	Number of Results
1979	1
1990	1
1997	1
2001	1
2004	1
2006	1
2007	1
2008	1
2009	7
2010	9
2011	9
2012	9
2013	16
2014	9
2015	18
2016	12
2017	10
2018	19
2019	24
2020	7
2021	5
2022	8
2023	1
2024	0

1

Clinical Outcomes of 42 Renal Cell Carcinoma Patients With Metastases Solely to the Lung Who Received Sorafenib as Second-line Systemic Therapy.

Miyake H, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A. Miyake H, et al. Anticancer Res. 2019 Feb;39(2):1067-1072. doi: 10.21873/anticanres.13214. Anticancer Res. 2019. PMID: 30711996

2

[Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].

Cai W, Yuan YC, Li MY, Kong W, Dong BJ, Chen YH, Zhang J, Xue W, Huang YR, Zhou LX, Huang JW. Cai W, et al. Zhonghua Zhong Liu Za Zhi. 2018 May 23;40(5):384-389. doi: 10.3760/cma.j.issn.0253-3766.2018.05.012. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 29860767 Chinese.

3

Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study.

Zhang HL, Qin XJ, Wang HK, Gu WJ, Ma CG, Shi GH, Zhou LP, Ye DW. Zhang HL, et al. Oncotarget. 2015 Nov 3;6(34):36870-83. doi: 10.18632/oncotarget.4874. Oncotarget. 2015. PMID: 26472104 Free PMC article.

4

Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.

Naito S, Tsukamoto T, Murai M, Fukino K, Akaza H. Naito S, et al. BJU Int. 2011 Dec;108(11):1813-9. doi: 10.1111/j.1464-410X.2011.10281.x. Epub 2011 Apr 11. BJU Int. 2011. PMID: 21481133 Clinical Trial.

5

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.

Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Flörcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS. Eichelberg C, et al. Eur Urol. 2015 Nov;68(5):837-47. doi: 10.1016/j.eururo.2015.04.017. Epub 2015 May 4. Eur Urol. 2015. PMID: 25952317 Free article. Clinical Trial.

6

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.

Grünwald V, Lin X, Kalanovic D, Simantov R. Grünwald V, et al. Eur Urol. 2016 Dec;70(6):1006-1015. doi: 10.1016/j.eururo.2016.05.010. Epub 2016 May 26. Eur Urol. 2016. PMID: 27238653

7

Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan.

Miyake H, Miyazaki A, Harada K, Fujisawa M. Miyake H, et al. Med Oncol. 2014 Jun;31(6):978. doi: 10.1007/s12032-014-0978-4. Epub 2014 May 4. Med Oncol. 2014. PMID: 24793747 Clinical Trial.

8

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI. Motzer RJ, et al. Lancet Oncol. 2013 May;14(6):552-62. doi: 10.1016/S1470-2045(13)70093-7. Epub 2013 Apr 16. Lancet Oncol. 2013. PMID: 23598172 Clinical Trial.

9

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.

Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, Wang X, Yan X, Guo J. Sheng X, et al. Oncotarget. 2016 May 10;7(19):27044-54. doi: 10.18632/oncotarget.7395. Oncotarget. 2016. PMID: 26894858 Free PMC article.

10

Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.

Zimmermann K, Schmittel A, Steiner U, Asemissen AM, Knoedler M, Thiel E, Miller K, Keilholz U. Zimmermann K, et al. Oncology. 2009;76(5):350-4. doi: 10.1159/000209961. Epub 2009 Mar 24. Oncology. 2009. PMID: 19321976

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

143 results

Results by year